Prothena Corp Public LTD CO PRTA
We take great care to ensure that the data presented and summarized in this overview for PROTHENA CORP PUBLIC LTD CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRTA
View all-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$163 Million8.41% of portfolio
-
Wellington Management Group LLP Boston, MA4.18MShares$58.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.86MShares$54.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$53.7 Million0.01% of portfolio
-
Palo Alto Investors LP Palo Alto, CA1.74MShares$24.4 Million4.0% of portfolio
-
State Street Corp Boston, MA1.67MShares$23.5 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY1.65MShares$23.2 Million0.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$17.7 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY1.1MShares$15.5 Million0.92% of portfolio
-
Geode Capital Management, LLC Boston, MA963KShares$13.5 Million0.0% of portfolio
Latest Institutional Activity in PRTA
Top Purchases
Top Sells
About PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Insider Transactions at PRTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2024
|
Karin L Walker Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$170,000
$34.0 P/Share
|
|
Jan 24
2024
|
Karin L Walker Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$65,000
$13.53 P/Share
|
|
Dec 20
2023
|
Karin L Walker Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,000
-66.78%
|
$185,000
$37.07 P/Share
|
|
Dec 20
2023
|
Karin L Walker Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$65,000
$13.53 P/Share
|
|
Nov 30
2023
|
Karin L Walker Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$170,000
$34.0 P/Share
|
|
Nov 30
2023
|
Karin L Walker Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$65,000
$13.53 P/Share
|
|
Oct 25
2023
|
Karin L Walker Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,000
-75.54%
|
$205,000
$41.31 P/Share
|
|
Oct 25
2023
|
Karin L Walker Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$65,000
$13.53 P/Share
|
|
Oct 11
2023
|
Brandon S. Smith Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,000
-94.45%
|
$188,000
$47.18 P/Share
|
|
Oct 11
2023
|
Brandon S. Smith Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+50.0%
|
$44,000
$11.12 P/Share
|
|
Oct 04
2023
|
Carol D. Karp Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
5,000
-93.37%
|
$230,000
$46.9 P/Share
|
|
Oct 04
2023
|
Carol D. Karp Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$60,000
$12.15 P/Share
|
|
Sep 27
2023
|
Michael J Malecek Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,000
-95.96%
|
$235,000
$47.8 P/Share
|
|
Sep 27
2023
|
Michael J Malecek Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$50,000
$10.27 P/Share
|
|
Sep 19
2023
|
Karin L Walker Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$260,000
$52.36 P/Share
|
|
Sep 19
2023
|
Karin L Walker Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$75,000
$15.04 P/Share
|
|
Sep 13
2023
|
Brandon S. Smith Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,000
-98.58%
|
$220,000
$55.72 P/Share
|
|
Sep 13
2023
|
Brandon S. Smith Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+50.0%
|
$44,000
$11.12 P/Share
|
|
Sep 13
2023
|
Hideki Garren Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$110,000
$55.48 P/Share
|
|
Sep 13
2023
|
Hideki Garren Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$48,000
$24.9 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 15K shares |
|---|
| Open market or private sale | 15K shares |
|---|